Updated:
Outcome Capital
Outcome Capital is an advisory and investment banking firm focused on life sciences and healthcare sectors. The company offers advisory and financial services...
Outcome Capital
Outcome Capital is an advisory and investment banking firm focused on life sciences and healthcare sectors. The company offers advisory and financial services for biotech, diagnostics, medical devices, and pharmaceutical companies. Outcome Capital was founded in 1998 in Reston, Virginia, and was formerly known as Wallace Willmore Cromwell Securities.
General information
Firm type
Asset Manager
Year founded
1998
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Oded Ben-Joseph
Managing Director
Arnold Freedman
Managing Director
Sector focus
Frequently asked questions
Is Outcome Capital an investment firm or an advisory firm?
Outcome Capital operates as a strategic advisory firm, not as an investment manager or pooled fund. It earns fees from M&A advisory, licensing transactions, and private placement mandates. The firm has not publicly disclosed raising a proprietary investment vehicle.
Who runs investment decisions at Outcome Capital?
Day-to-day execution and client engagement are led by Managing Directors Oded Ben-Joseph and Arnold Freedman. Ben-Joseph's background spans operations and strategy roles in pharmaceutical and medical-device companies, while Freedman has a track record in investment banking and sell-side mandates across the life sciences. All transaction decisions involve the managing director team.
Which sectors does Outcome Capital explicitly avoid?
Outcome Capital focuses tightly on healthcare: life sciences, healthcare services, and digital health. It does not market services in verticals such as enterprise software, fintech, consumer packaged goods, or real estate, and its published mandates have not extended into adjacent regulated industries like defense contracting or pure industrial technology.
Does Outcome Capital participate in fund commitments or only direct deals?
The firm structures direct transactions — sell-side sales, buy-side acquisitions, private placements, and licensing deals — rather than committing to third-party venture or growth equity funds. Its growth capital practice facilitates company-level minority placements and structured debt, but it does not operate as a fund-of-funds or limited partner.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: